GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$82.12
2.08 (2.60%)
▲
5d:
+5.93%
30d:
-3.17%
90d:
-4.79%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GMED appears deeply undervalued. Market expects -5.5% annual earnings decline despite 67% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: GMED appears deeply undervalued. Market expects -5.5% annual earnings decline despite 67% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$131.61
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$81.72
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $82.12, which is considered slightly high relative to its 30-day fair value range of $78.09 to $82.96. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.0) compared to its historical average (18.9). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $83.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $108.64 (+32.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $83.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $108.64 (+32.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$78.09 -
$82.96
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.3% below Wall St target ($108.64)
Trading Range Analysis
30-Day Trading Range
$78.09 -
$82.96
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$74.67
Resistance Level
$83.57
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.96
Wall Street Target
$108.64
(+32.3%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
16.0 vs 18.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$77.60
(-6%)
2-Year Target
$73.34
(-11%)
3-Year Target
$69.30
(-16%)
3-Yr Target (if PE normalizes)
(PE: 16→19)
$82.07
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.5%)
$143.07
(+74%)
Base:
(SPY PE: 16.0, Growth: 8.5%)
$104.84
(+28%)
Bear:
(PE: 13.6, Growth: 8.5%)
$89.11
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 18.70 | Current EPS (TTM): $4.28
Bull Case
$105.85
(+29%)
Analyst growth 20.2%, PE expands to 20.6
Base Case
$96.22
(+17%)
Market implied 20.2%, PE stable at 18.7
Bear Case
$54.43
(-34%)
Severe decline -20.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.0 to 18.9
Stabilization Target:
$97.25
(+18.4%)
PE Expansion Potential:
+18.4%
Share & Embed Analysis
Last updated: June 24, 2026 6:16 PM ET
Data refreshes hourly during market hours. Next update: 7:16 PM
Data refreshes hourly during market hours. Next update: 7:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 67 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
